Evidence map›Paper›PMID 31658732›Full record

ArticleBrain sciences2019

Efficacy of Cell-Based Therapies for Traumatic Brain Injuries.

Matthew R Chrostek, Emily G Fellows, Winston L Guo, William J Swanson, Andrew T Crane, Maxim C Cheeran, Walter C Low, Andrew W Grande

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Matthew R ChrostekDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. chros005@umn.edu.ORCID 0000-0002-9457-1431
Emily G FellowsDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. fello064@umn.edu.
Winston L GuoDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. guoxx838@umn.edu.
William J SwansonDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. swan2166@umn.edu.
Andrew T CraneDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. atcrance@umn.edu.
Maxim C CheeranDepartment of Veterinary Population Medicine, University of Minnesota College of Veterinary Medicine, St. Paul, MN 55108, USA. cheeran@umn.edu.
Walter C LowDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. lowwalt@umn.edu.
Andrew W GrandeDepartment of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA. grande@umn.edu.ORCID 0000-0002-6474-7969
University of Minnesota Medical Center · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injuries (TBIs) are a leading cause of death and disability. Additionally, growing evidence suggests a link between TBI-induced neuroinflammation and neurodegenerative disorders. Treatments for TBI patients are limited, largely focused on rehabilitation therapy, and ultimately, fail to provide long-term neuroprotective or neurorestorative benefits. Because of the prevalence of TBI and lack of viable treatments, new therapies are needed which can promote neurological recovery. Cell-based treatments are a promising avenue because of their potential to provide multiple therapeutic benefits. Cell-based therapies can promote neuroprotection via modulation of inflammation and promote neurorestoration via induction of angiogenesis and neurogenesis. Neural stem/progenitor cell transplantations have been investigated in preclinical TBI models for their ability to directly contribute to neuroregeneration, form neural-like cells, and improve recovery. Mesenchymal stem cells (MSCs) have been investigated in clinical trials through multiple different routes of administration. Intravenous administration of MSCs appears most promising, demonstrating a robust safety profile, correlation with neurological improvements, and reductions in systemic inflammation following TBI. While still preliminary, evidence suggests cell-based therapies may become a viable treatment for TBI based on their ability to promote neuroregeneration and reduce inflammation.

Indexed as

inflammationmesenchymal stem cellsneural stem cellsneuroregenerationstem cellstraumatic brain injury

Identifiers

PMID31658732
PMCPMC6826445
OpenAlexW2979360760

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.